IMA logo

IMAGENEBIO INC

IMANASDAQ
πŸ† #4295 by market capUS Equity
$4.18β€”
Last available close Β· quote unavailable
πŸ””
Track IMA
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–² 0.7%
14dβ–² 3.6%
30dβ–Ό 15.5%
ytdβ–Ό 39.2%
1yβ–Ό 52.5%
🏦Market Cap
$48M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
5.2x
Fair
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
β€”
52-Week Range
$3.88 – $9.10
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
11.3M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$800,000
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
5.2x
EPS (TTM)
$-5.34
Dividend Yield
β€”
Dilution (1yr)
+693.1%
IMA logo

IMAGENEBIO INC

IMA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$800Kβ–Ό βˆ’77.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-29.1%β–Ό βˆ’151.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$48Mβ–² +30.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$48Mβ–² +4.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.2Mβ–² +693.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$25Mβ–Ό βˆ’$7M YoY
StockOtter Β· stockotter.space

About IMAGENEBIO INC

ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.